NEW YORK (GenomeWeb News) – Mizuho Securities USA has initiated coverage of Exact Sciences with a Buy rating and a $13 price target.

The Madison, Wis.-based firm is developing the Cologuard test, a stool-based DNA test for colorectal cancer screening. Mizuho analyst Peter Lawson said in a note that there is a "large untapped revenue opportunity available to Cologuard of over $1.2 billion in the US with limited competition."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.